Prognostic and predictive biomarker developments in multiple myeloma
CT Wallington-Beddoe, RL Mynott - Journal of hematology & oncology, 2021 - Springer
New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …
decision-making, or prediction, are needed since patients are currently managed in a similar …
Genomic complexity of multiple myeloma and its clinical implications
Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial… - Blood, The Journal …, 2016 - ashpublications.org
Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …
Multiple myeloma: Available therapies and causes of drug resistance
V Pinto, R Bergantim, HR Caires, H Seca… - Cancers, 2020 - mdpi.com
Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely
understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number …
understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number …
IMWG consensus on risk stratification in multiple myeloma
Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which
translates to variable response to treatment and outcome. With the recent increase in …
translates to variable response to treatment and outcome. With the recent increase in …
The genetic architecture of multiple myeloma
Based on the clinical features of myeloma and related malignancies of plasma cells, it has
been possible to generate a model system of myeloma progression from a normal plasma …
been possible to generate a model system of myeloma progression from a normal plasma …
Evolutionary biology of high-risk multiple myeloma
The outcomes for the majority of patients with myeloma have improved over recent decades,
driven by treatment advances. However, there is a subset of patients considered to have …
driven by treatment advances. However, there is a subset of patients considered to have …
Multiple myeloma with high-risk cytogenetics and its treatment approach
I Hanamura - International Journal of Hematology, 2022 - Springer
Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …
Interpretation of cytogenetic results in multiple myeloma for clinical practice
AM Rajan, SV Rajkumar - Blood cancer journal, 2015 - nature.com
The interpretation of cytogenetic abnormalities in multiple myeloma (MM) is often a
challenging task. MM is characterized by several cytogenetic abnormalities that occur at …
challenging task. MM is characterized by several cytogenetic abnormalities that occur at …